Aquestive Therapeutics, Inc.
AQST
$6.51
-$0.18-2.76%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.00M | 8.72M | 11.87M | 13.54M | 20.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.00M | 8.72M | 11.87M | 13.54M | 20.10M |
| Cost of Revenue | 4.56M | 3.65M | 4.52M | 4.44M | 4.53M |
| Gross Profit | 5.44M | 5.07M | 7.35M | 9.11M | 15.57M |
| SG&A Expenses | 12.71M | 19.07M | 16.01M | 12.13M | 11.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.37M | 28.09M | 25.45M | 21.83M | 20.04M |
| Operating Income | -11.37M | -19.37M | -13.58M | -8.29M | 55.00K |
| Income Before Tax | -13.55M | -22.93M | -17.07M | -11.51M | -2.75M |
| Income Tax Expenses | -- | -- | -14.00K | -- | -- |
| Earnings from Continuing Operations | -13.55M | -22.93M | -17.06M | -11.51M | -2.75M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.55M | -22.93M | -17.06M | -11.51M | -2.75M |
| EBIT | -11.37M | -19.37M | -13.58M | -8.29M | 55.00K |
| EBITDA | -11.23M | -19.23M | -13.41M | -8.13M | 260.00K |
| EPS Basic | -0.14 | -0.24 | -0.19 | -0.13 | -0.03 |
| Normalized Basic EPS | -0.09 | -0.15 | -0.11 | -0.08 | -0.03 |
| EPS Diluted | -0.14 | -0.24 | -0.19 | -0.13 | -0.03 |
| Normalized Diluted EPS | -0.09 | -0.15 | -0.11 | -0.08 | -0.03 |
| Average Basic Shares Outstanding | 99.33M | 95.50M | 91.20M | 91.08M | 90.91M |
| Average Diluted Shares Outstanding | 99.33M | 95.50M | 91.20M | 91.08M | 90.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |